Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

carilion materials management - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - carefully consider the potential benefits and risks of indomethacin extended-release capsules usp 75 mg and other treatment options before deciding to use indomethacin extended-release capsules usp 75 mg. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). warnings indomethacin extended-release capsules usp 75 mg has been found effective in active stages of the following: 1. moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. moderate to severe ankylosing spondylitis. 3. moderate to severe osteoarthritis. 4. acute painful shoulder (bursitis and/or tendinitis). indomethacin extended-release capsules usp 75 mg are not recommended for the treatment of acute gouty arthritis. indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. in such instances the steroid dosage should be reduced slowly and the patients fo

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hospira, inc. - indomethacin sodium (unii: 0imx38m2gg) (indomethacin - unii:xxe1cet956) - indomethacin 1 mg - indomethacin for injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray. indomethacin for injection is contraindicated in: neonates with proven or suspected infection that is untreated; neonates who are bleeding, especially those with active intracranial hemorrhage or gastrointestinal bleeding; neonates with thrombocytopenia; neonates with coagulation defects; neonates with or who are suspected of having necrotizing enterocolitis; neonates with significant impairment of renal function; neonates with congenital heart disease in whom patency of the ductus arteriosus

Australia - engleză - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hydrophobic colloidal silica anhydrous; chlorophyllin-copper complex aluminium lake - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; hydrophobic colloidal silica anhydrous; magnesium stearate - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; hydrophobic colloidal silica anhydrous; magnesium stearate - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

clinect nz pty limited - perindopril erbumine 2mg - tablet - 2 mg - active: perindopril erbumine 2mg excipient: lactose magnesium stearate - perindopril is indicated for: · the treatment of hypertension.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

clinect nz pty limited - perindopril erbumine 4mg - tablet - 4 mg - active: perindopril erbumine 4mg excipient: lactose magnesium stearate - perindopril is indicated for: · the treatment of hypertension.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

clinect nz pty limited - perindopril erbumine 8mg - tablet - 8 mg - active: perindopril erbumine 8mg excipient: lactose magnesium stearate - perindopril is indicated for: · the treatment of hypertension.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

apotheca, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings) indomethacin has been found effective in active stages of the following: - moderate to severe rheumatoid arthritis including acute flares of chronic disease. - moderate to severe ankylosing spondylitis. - moderate to severe osteoarthritis. - acute painful shoulder (bursitis and/or tendinitis). - acute gouty arthritis. indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see description). indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings: anaphylactic/anaphylactoid reactions

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hetero drugs ltd., - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 25 mg - c19 h16 clno4        m.w. 357.79 indomethacin, usp is practically insoluble in water and sparingly soluble in alcohol. it has a pka of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. each capsule for oral administration contains 25 mg or 50 mg of indomethacin and the following inactive ingredients: lactose monohydrate, sodium lauryl sulphate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate. the hard gelatin shell consists of gelatin, titanium dioxide usp, fd & c blue 1, d & c yellow 10. the capsules are printed with black ink containing black iron oxide e172 dye.